Vor Biopharma

Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. It is a clinical-stage cell therapy company that combines a novel patient engineering approach with therapies to provide a single company solution for patients suffering from hematological malignancies. The company was founded by Aleks Radovic-Moreno and Siddhartha Mukherjee on December 30, 2015 and is headquartered in Cambridge, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:

Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of May 1, 2024, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 31,750 shares of Vor Bio's common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 47,625 shares of Vor Bio's common stock to six newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board of Directors. Dr. Namouni currently serves as President of Research & Development at Blueprint Medicines, bringing a wealth of industry experience and expertise to Vor Bio's Board.

Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors

Vor Biopharma (VOR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why You Shouldn't Bet Against Vor Biopharma (VOR) Stock

Adicet Bio, Inc.

Arbe Robotics Ltd

KORU Medical Systems Inc

Lantronix

CarParts.com, Inc.

PowerFleet Inc

In most cases, investors should stay away from penny stocks. They're wild, they're unpredictable and they tend to lose their stakeholders money more so than they return.

The Penny Stock A-List: 7 High-Profile Companies on the Verge of Greatness

CAMBRIDGE, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full year ended December 31, 2023, and provided a business update.

Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

CAMBRIDGE, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the Oppenheimer 34th Annual Healthcare Life Sciences Conference.

Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Vor Bio (VOR) stock gains after dosing the first patient in its phase I/II study of novel cell therapy, VCAR33 (Allogenic), to treat AML. The company extends its cash runway into the second half of 2025.

Vor Bio (VOR) Up on Positive Update From AML Cell Therapy Study

CAMBRIDGE, Mass., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, announced today it has dosed the first patient in VBP301, its Phase 1/2, multicenter, open-label, first-in-human study of VCAR33ALLO. The Company has extended its cash runway into the second half of 2025.

Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update

CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the JMP Securities Hematology and Oncology Summit.

Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit

CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today presented updated clinical data from patients treated in VBP101, its Phase 1/2a multicenter, open-label, first-in-human study of trem-cel (VOR33) in patients with acute myeloid leukemia (AML). Guenther Koehne, MD, PhD, Deputy Director and Chief of Blood & Marrow Transplant and Hematologic Oncology at Miami Cancer Institute of Baptist Health South Florida will present these data on November 10, 4:15PM PST, in an oral presentation at the ASTCT/EBMT 6th International Conference on Relapse After Transplant and Cellular Therapy (HSCT²) in Los Angeles, California.

Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference

CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended September 30, 2023, and provided a business update.

Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update

CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that preclinical and clinical data supporting the Company's novel platform and approach for treating acute myeloid leukemia (AML), will be presented at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, being held from December 9-12, 2023, in San Diego, CA.

Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio's Novel eHSC and CAR-T Platform

CAMBRIDGE, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended June 30, 2023, and provided a business update.

Vor Bio Reports Second Quarter 2023 Financial Results and Provides Company Update

CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, will host in-person 1x1 investor meetings at the 2023 Wedbush PacGrow Healthcare Conference.

Vor Bio to Participate in the Wedbush PacGrow Healthcare Conference

Bellerophon Therapeutics

Cibus Inc

Innovative Eyewear Inc

Panbela Therapeutics Inc

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In July - Cibus (NASDAQ:CBUS), Bellerophon Therapeutics (NASDAQ:BLPH)

CAMBRIDGE, Mass., June 09, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today presented updated clinical data from patients treated in VBP101, its Phase 1/2a multicenter, open-label, first-in-human study of trem-cel (formerly VOR33) in patients with acute myeloid leukemia (AML). These data were presented by Guenther Koehne, MD, PhD, Deputy Director and Chief of Blood & Marrow Transplant and Hematologic Oncology at Miami Cancer Institute of Baptist Health South Florida in a poster presentation at the European Hematology Association (EHA) 2023 Congress in Frankfurt, Germany.

Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio's Platform

CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, will present and host in-person 1x1 investor meetings at the Goldman Sachs 44th Annual Global Healthcare Conference.

Vor Bio to Participate in the Goldman Sachs Healthcare Conference

CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended March 31, 2023, and provided a business update.

Vor Bio Reports First Quarter 2023 Financial Results and Provides Company Update

The mean of analysts' price targets for Vor Biopharma Inc. (VOR) points to a 172.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

How Much Upside is Left in Vor Biopharma Inc. (VOR)? Wall Street Analysts Think 172.06%

Vor Biopharma Inc. is the brainchild of Dr. Siddhartha Mukherjee. Its core idea is to make CAR-Ts safer by using stem cells.

Vor Biopharma: Very Interesting Idea For Improving CAR-T Through Stem Cells

Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, reported its financial results for the three-month period and full year that ended December 31, 2022, and provided a business update. The post Vor Bio Announces Q4 And FY 2022 Results appeared first on Pulse 2.0.

Vor Bio Announces Q4 And FY 2022 Results

CAMBRIDGE, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full year ended December 31, 2022, and provided a business update.

Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

CAMBRIDGE, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, presented clinical data from VBP101, its Phase 1/2a multicenter, open-label, first-in-human study of trem-cel (previously VOR33) in patients with acute myeloid leukemia (AML). In the first patient, trem-cel maintained hematopoiesis through three cycles of Mylotarg (gemtuzumab ozogamicin), which was well-tolerated at the initial dose level of 0.5 mg/m2. A second patient has successfully received a trem-cel transplant and engrafted normally. These data were presented today by Miguel-Angel Perales, MD, Chief, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center in a late-breaking poster at the 2023 Tandem Meetings (Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®) in Orlando, FL.

First AML Patient Transplanted with Vor Bio's Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg™ Cycles at Initial Dose Level

CAMBRIDGE, Mass., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that clinical data from the first patient treated in VBP101, its Phase 1/2a multicenter, open-label, first-in-human study of trem-cel (formerly VOR33) in patients with acute myeloid leukemia (AML) has been accepted as a late-breaking poster presentation at the 2023 Tandem Meetings, the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, taking place February 15-19 in Orlando, Florida.

News for Vor Biopharma Stock (VOR)